Tag

Eli Lilly

3 articles

After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more

Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO's decision on double patenting, updates from…

Gaurav Mishra · 28 Jun 2021

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates…

Gaurav Mishra · 24 May 2021

Patent Infringement Claim on Cancer Treatment Drug

The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim…

Gaurav Mishra · 9 Jul 2015

IP Rights

News & Analysis

Practice & Business

Tech, Media & Society

Specialised

Eli Lilly

After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Patent Infringement Claim on Cancer Treatment Drug